Advertisement
Canada markets closed

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7321
    +0.0020 (+0.27%)
     

  • CRUDE OIL

    83.41
    +0.05 (+0.06%)
     

  • Bitcoin CAD

    90,759.51
    -545.44 (-0.60%)
     

  • CMC Crypto 200

    1,429.19
    +14.43 (+1.02%)
     

  • GOLD FUTURES

    2,335.80
    -6.30 (-0.27%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,672.50
    +65.75 (+0.37%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6835
    -0.0015 (-0.22%)
     

Small Caps of IBB Underperform from August 25–31

Peter Neil

XBI Leads the Biotech ETFs for August 25–31

(Continued from Prior Part)

Small caps of IBB underperform

In the small-cap segment by market cap (capitalization), the top ten small-cap stocks from the SPDR S&P Biotech ETF (XBI) outperformed the top ten small-cap stocks from the iShares Nasdaq Biotechnology ETF (IBB) for August 25–31.

XBI’s top ten small-cap stocks returned 11.37%, while IBB’s top ten small-cap stocks gained 10.74%. Thus, IBB’s small-cap stocks underperformed.

The above chart reflects the performance of the top ten small-cap stocks for IBB and XBI.

Ariad and Prothena lead small-cap stocks

ADVERTISEMENT

Ariad Pharmaceuticals (ARIA) stock rose 46.58% on news that Baxalta (BXLT) is in talks to acquire ARIA. ARIA has a weight of 0.24%. It closed at $9.44 on August 31, 2015. BXLT recently rejected a $30 billion offer from Shire (SHPG).

Prothena (PRTA) has a weight of 1.39% in XBI and 0.18% in IBB. PRTA closed at $57.83 on August 31. The stock bounced back from the oversold position and rose 16.98% for August 25–31. However, the stock on August 31 was still trading below its 50-day and 20-day moving averages.

Tetraphase Pharmaceuticals (TTPH) rose 13.37%. According to a company press release, Tetraphase will present 11 data presentations on the company’s lead drug, eravacycline, along with its pre-clinical pipeline program for TP-271 at the Interscience Conference of Antimicrobial Agents and Chemotherapy (or ICAAC) and the International Congress of Chemotherapy and Infection (or ICC). TTPH has a weight of 0.22%.

IBB have stocks like Gilead Sciences (GILD, Biogen (BIIB), Celgene (CELG), and other top biotech stocks in its portfolio.

Continue to Next Part

Browse this series on Market Realist: